Open AccessRationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
Author(s) -
Ю. В. Муравьев,
Г. И. Гриднева,
Л А Муравьева,
Н. В. Муравьева,
А. В. Алексеева,
К. С. Нурбаева,
К. М. Михайлов,
Andrei Rozov
Publication year - 2018
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2018-4-101-105
Subject(s) - tofacitinib , medicine , rheumatoid arthritis , discontinuation , sulfasalazine , leflunomide , prednisolone , methotrexate , adverse effect , rheumatology , pharmacology , disease , ulcerative colitis